Pieris, sanofi in Anticalin deal

Pieris AG (Freising-Weihenstephan, Germany) will use its Anitcalin technology to discover Anticalin candidates against targets selected by sanofi-aventis Group (Euronext:SAN; NYSE:SNY) and sanofi's Sanofi Pasteur vaccines division. Anticalins are engineered proteins with antibody-like binding properties. The deal initially includes two targets with an option to select four additional targets. Sanofi and its vaccine division will be responsible for further development and commercialization of all products. ...